Pregnancies and Neonatal Outcomes in Patients with Sickle Cell Disease (SCD): Still a (High-)Risk Constellation?

Overview

Journal J Pers Med

Date 2021 Sep 28

PMID 34575647

Citations 1

Authors

Pia Proske

Laura Distelmaier

Carmen Aramayo-Singelmann

Nikolaos Koliastas

Antonella Iannaccone

Maria Papathanasiou

Christian Temme

Hannes Klump

Veronika Lenz

Michael Koldehoff

Alexander Carpinteiro

Hans Christian Reinhardt

Angela Koninger

Alexander Roth

Raina Yamamoto

Ulrich Duhrsen

Ferras Alashkar

Affiliations

Soon will be listed here.

Abstract

Background: This monocentric study conducted at the University Hospital of Essen aims to describe maternal and fetal/neonatal outcomes in sickle cell disease (SCD) documented between 1996 to 2021 (N = 53), reflecting the largest monocentric analysis carried out in Germany.

Methods/results: 46 pregnancies in 22 patients were followed. None of the patients died. In total, 35% (11/31) of pregnancies were preterm. 15 pregnancies in eight patients were conceived on hydroxycarbamide (HC), of which nine had a successful outcome and three were terminated prematurely. There was no difference regarding the rate of spontaneous abortions in patients receiving HC compared to HC-naive patients prior to conception. In patients other than HbS/C disease, pregnancies were complicated by vaso-occlusive crises (VOCs)/acute pain crises (APCs) (96%, 23/24); acute chest syndrome (ACS) (13%, 3/24), transfusion demand (79%, 19/24), urinary tract infections (UTIs) (42%, 10/24) and thromboembolic events (8%, 2/24). In HbS/C patients complications included: VOCs/APCs (43%, 3/7; ACS: 14%, 1/7), transfusion demand (14%, 1/7), and UTIs (14%, 1/7). Independent of preterm deliveries, a significant difference with respect to neonatal growth in favor of neonates from HbS/C mothers was observed.

Conclusion: Our data support the results of previous studies, highlighting the high rate of maternal and fetal/neonatal complications in pregnant SCD patients.

Citing Articles

Special Issue "Personalized Medicine in Blood Disease of Children".

Ceci A, Kountouris P, Didio A, Bonifazi F J Pers Med. 2024; 14(3).

PMID: 38541027 PMC: 10971618. DOI: 10.3390/jpm14030285.

References

Whittington J, Magann E, Ounpraseuth S, Chang J, Whitcombe D, Morrison J . Evidence for Prophylactic Transfusion during Pregnancy for Women with Sickle Cell Disease. South Med J. 2021; 114(4):231-236. DOI: 10.14423/SMJ.0000000000001233. View

Hendrickson J, Tormey C . Understanding red blood cell alloimmunization triggers. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):446-451. PMC: 6142457. DOI: 10.1182/asheducation-2016.1.446. View

Smith-Whitley K . Complications in pregnant women with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):359-366. PMC: 6913482. DOI: 10.1182/hematology.2019000039. View

Chou S, Jackson T, Vege S, Smith-Whitley K, Friedman D, Westhoff C . High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013; 122(6):1062-71. DOI: 10.1182/blood-2013-03-490623. View

Wong T, Brandow A, Lim W, Lottenberg R . Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014; 124(26):3850-7. PMC: 4271176. DOI: 10.1182/blood-2014-08-435768. View

Piel F, Steinberg M, Rees D . Sickle Cell Disease. N Engl J Med. 2017; 376(16):1561-1573. DOI: 10.1056/NEJMra1510865. View

Elenga N, Adeline A, Balcaen J, Vaz T, Calvez M, Terraz A . Pregnancy in Sickle Cell Disease Is a Very High-Risk Situation: An Observational Study. Obstet Gynecol Int. 2016; 2016:9069054. PMC: 4926018. DOI: 10.1155/2016/9069054. View

Nickel R, Hendrickson J, Fasano R, Meyer E, Winkler A, Yee M . Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion. 2015; 56(1):107-14. DOI: 10.1111/trf.13379. View

Chou S, Alsawas M, Fasano R, Field J, Hendrickson J, Howard J . American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020; 4(2):327-355. PMC: 6988392. DOI: 10.1182/bloodadvances.2019001143. View

10.

Schonewille H, Prinsen-Zander K, Reijnart M, van de Watering L, Zwaginga J, Meerman R . Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation. Transfusion. 2015; 55(12):2912-9. DOI: 10.1111/trf.13231. View

11.

Da Costa D, Pellegrino Jr J, Guelsin G, Ribeiro K, Gilli S, Castilho L . Molecular matching of red blood cells is superior to serological matching in sickle cell disease patients. Rev Bras Hematol Hemoter. 2013; 35(1):35-8. PMC: 3621633. DOI: 10.5581/1516-8484.20130012. View

12.

Tormey C, Stack G . The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2008; 49(3):505-12. DOI: 10.1111/j.1537-2995.2008.02014.x. View

13.

Babah O, Aderolu M, Oluwole A, Afolabi B . Towards zero mortality in sickle cell pregnancy: A prospective study comparing haemoglobin SS and AA women in Lagos, Nigeria. Niger Postgrad Med J. 2019; 26(1):1-7. DOI: 10.4103/npmj.npmj_177_18. View

14.

Oakley L, Awogbade M, Brien S, Briley A, Chorozoglou M, Drasar E . Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial. Trials. 2020; 21(1):347. PMC: 7171865. DOI: 10.1186/s13063-020-4212-8. View

15.

Ballas S, Barton F, Waclawiw M, Swerdlow P, Eckman J, Pegelow C . Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006; 4:59. PMC: 1569824. DOI: 10.1186/1477-7525-4-59. View

16.

Vichinsky E, Earles A, Johnson R, HOAG M, Williams A, Lubin B . Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990; 322(23):1617-21. DOI: 10.1056/NEJM199006073222301. View

17.

Natukunda B, Schonewille H, Ndugwa C, Brand A . Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion. 2009; 50(1):20-5. DOI: 10.1111/j.1537-2995.2009.02435.x. View

18.

Jain D, Atmapoojya P, Colah R, Lodha P . Sickle Cell Disease and Pregnancy. Mediterr J Hematol Infect Dis. 2019; 11(1):e2019040. PMC: 6613624. DOI: 10.4084/MJHID.2019.040. View

19.

Boafor T, Olayemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C . Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2015; 123(5):691-8. DOI: 10.1111/1471-0528.13786. View

20.

Ballas S . The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020010. PMC: 6951351. DOI: 10.4084/MJHID.2020.010. View